Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early adjunctive eptifibatide after IV thrombolysis in non-large vessel acute disabling stroke
ChiCTR2600120216Phase 3Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jun 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in brain infarction comparing eptifibatide with Control: eptifibatide placebo (2 arms). Primary endpoints: mRS score 0-1 at 90 days, Symptomatic intracranial hemorrhage within 48 hours after treatment and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
eptifibatide
03
Conditions
brain infarction
Beyond the preview
Go deeper on ChiCTR2600120216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120216.